arrow_back Trending Legislation
Share share

Neuroscience Center of Excellence: Supporting Brain Disease Drug Development

The act authorizes the Secretary of Health and Human Services to establish a Neuroscience Center of Excellence within the FDA. The Center is tasked with coordinating collaborations and supporting the development of medical products for neurological and psychiatric diseases. The legislation includes programs regarding patient-focused drug development, natural history studies, and the impact of COVID-19 on these conditions.
Key points
Establishment of a Neuroscience Center of Excellence to support the development and approval of medical products for neurological diseases.
Implementation of a patient-focused drug development program, including the collection of patient experience data.
Examination of the impact of the COVID-19 pandemic on neurological and psychiatric diseases and strategies for rapid medical product development.
Authorization of $25 million for fiscal years 2023 through 2027 to carry out the Center's activities.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Neuroscience Center of Excellence Act of 2021
Print number: S 3427
Sponsor: Sen. Collins, Susan M. [R-ME]
Process start date: 2021-12-16
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Neuroscience Center of Excellence: Supporting Brain Disease Drug Development

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 3427.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-12-16.

What are the main provisions?

Key points include:

  • Establishment of a Neuroscience Center of Excellence to support the development and approval of medical products for neurological diseases.
  • Implementation of a patient-focused drug development program, including the collection of patient experience data.
  • Examination of the impact of the COVID-19 pandemic on neurological and psychiatric diseases and strategies for rapid medical product development.
  • Authorization of $25 million for fiscal years 2023 through 2027 to carry out the Center's activities.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Collins, Susan M. [R-ME].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Analysis and Potential Impact of S 3427

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health